Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis Dividend Announcement
• Novartis announced a semi annually dividend of $3.78 per ordinary share which will be made payable on . Ex dividend date: 2024-09-24
• Novartis annual dividend for 2024 was $7.55
• Novartis annual dividend for 2023 was $3.47
• Novartis's trailing twelve-month (TTM) dividend yield is 7.41%
• Novartis's payout ratio for the trailing twelve months (TTM) is 43.31%
• Novartis's dividend growth over the last five years (2018-2023) was 5.40% year
• Novartis's dividend growth over the last ten years (2013-2023) was 4.35% year
Novartis Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-09-24 | $3.78 | semi annually | |
2024-03-07 | $3.78 | semi annually | 2024-04-19 |
2023-03-09 | $3.47 | semi annually | 2023-03-20 |
2022-03-08 | $3.36 | semi annually | 2022-03-17 |
2021-03-04 | $3.38 | semi annually | 2021-03-15 |
2020-03-03 | $3.04 | semi annually | 2020-03-12 |
2019-03-04 | $2.57 | semi annually | 2019-03-13 |
2018-03-06 | $2.67 | semi annually | 2018-04-25 |
2017-03-01 | $2.46 | semi annually | 2017-04-20 |
2016-02-24 | $2.47 | semi annually | 2016-04-15 |
2015-03-02 | $2.52 | semi annually | 2015-04-20 |
2014-02-27 | $2.72 | semi annually | 2014-04-10 |
2013-02-26 | $2.27 | semi annually | 2013-04-05 |
Novartis Dividend per year
Novartis Dividend growth
Novartis Dividend Yield
Novartis current trailing twelve-month (TTM) dividend yield is 7.41%. Interested in purchasing Novartis stock? Use our calculator to estimate your expected dividend yield:
Novartis Financial Ratios
Novartis Dividend FAQ
Other factors to consider when evaluating Novartis as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Novartis stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Novartis's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Novartis publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Novartis distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Novartis are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Novartis sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Novartis distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Novartis declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Novartis's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Novartis's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.